Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05669755 · ClinicalTrials.gov registry record · Phase 3
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
A Phase 3 study of Cardiovascular Disease, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 3
- Development phase
- 7,101
- Enrollment target
- 20
- Study locations
NCT05669755: Active Phase 3 study of Cardiovascular Disease, sponsored by Novo Nordisk A/S.
NCT05669755 is a Phase 3 study of Cardiovascular Disease that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 7,101 participants, above the 2,646-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (168% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05669755, a Phase 3 study of Cardiovascular Disease, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 7,101 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease. Participants will either get CagriSema or a dummy medicine (also called "placebo") which has no effect on the body. Which treatment participants will get will be decided by chance. Participant's chance of getting CagriSema or placebo is the same. Participants will inject the study medicine once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for up to 4.5 years.
Primary Outcome
Measured in days.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Semaglutide
- DRUG Cagrilintide
Study Locations (20)
California
- National Heart Institute Cal - Beverly Hills
- Valley Clinical Trials - Covina
- Scripps Wht Diab Inst La Jolla - La Jolla
- First Valley Medical Group - Lancaster
- Clinical Trials Research_Sacramento - Lincoln
- Torrance Clin Res Inst, Inc. - Lomita
- Pacific Clinical Studies - Los Alamitos
- Monterey Endocrine & Diabetes Institute, Inc - Monterey
- Valley Clinical Trials, Inc. - Northridge
- Desert Oasis Hlthcr Med Group - Palm Springs
- Western University of Health Sciences - Pomona
- Linda Vista Health Care Ctr - San Diego
- N America Res Inst - San Dimas - San Dimas
- Encompass Clinical Research_Spring Valley - Spring Valley
- Lundquist Inst.-Biom Inno-UCLA - Torrance
Alabama
- Univ of Alabama Birmingham - Birmingham
- Chambliss Clinical Trials LLC - Montgomery
Arizona
- Honor Health - Scottsdale
Connecticut
- Bridgeport Hospital - Bridgeport
Florida
- Innovative Research of W FL - Clearwater
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,101 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2027-10-13 |
| Phase | Phase 3 |
What the registry record for NCT05669755 still lists
NCT05669755 is an interventional study that assigns participants to a tested intervention. Its 7,101 participants enrollment target places it among the larger protocols in the corpus, above the 2,646-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (168% higher).
The record links to 1 condition, with Cardiovascular Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05669755 names 20 study sites across 5 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT05669755 about?
NCT05669755 is a clinical study titled "REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels". This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease. Participants will either get CagriSema or a dummy medicine (also called "placebo") which has no effect on the body. Which treatment participan...
What is the current status of trial NCT05669755?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 7,101 participants. The study started on 2023-03-01. Estimated completion is 2027-10-13.
What conditions does trial NCT05669755 study?
This clinical trial studies the following conditions: Cardiovascular Disease.
What interventions are being tested in trial NCT05669755?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG), Cagrilintide (DRUG).
Who is sponsoring clinical trial NCT05669755?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05669755 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05669755's enrollment target sits among peer trials
7,101 14th of 137 higher than 124 of 137 other Cardiovascular Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
RECRUITING · Phase 3
-
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
RECRUITING · Phase 3
-
VITAL Rhythm Study
ACTIVE NOT RECRUITING · Phase 3
-
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
ACTIVE NOT RECRUITING · Phase 3
-
Vitamin D and Omega-3 Trial (VITAL)
ACTIVE NOT RECRUITING · Phase 3
-
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06843720 · 7,100 participants · NA
Expanding Access to Cervical Cancer Screening Through Primary HR-HPV Testing and Self-sampling: a Multicomponent Intervention for Safety Net Health Systems
- NCT05049837 · 7,200 participants
PROSPECT - Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification
- NCT06714929 · 7,200 participants · NA
Advancing Water Security: A Community Participatory School-Based Hydration Intervention
- NCT00260585 · 7,000 participants
Esophageal Cancer Risk Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI